SecBot SecBot

GOSS

Gossamer Bio, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001728117 Biotech & Drug Discovery
$9.15 −0.45 (−4.74%)
Oct 26 4:00 PM ET · prev $9.60
Market cap
$57.9M
Micro cap
Consensus
Buy
62% Buy or better · 13 analysts
Median target
$95.00
+938% · range $22.40–160.00
Next earnings
Nov 3
in 8 days · EPS est. −$3.93
1 year
−95.2%
from $191.20 · Oct 27
30 days
−20.6%
from $11.52
52-week range
$8.43–303.20
−97% from high · low Oct 19
Avg volume 20D
263.4K
shares / day
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · since Mar 19
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
15
analyzed by SecBot
SecBot read BEARISH 8 reports · 90 days
Balance 4 bearish · 0 bullish · 1 mixed · 3 neutral oldest → newest, height = score
Avg score ·High conf. 6/8 ·Next Earnings date, Nov 3, 2026
Strongest BEARISH D. E. Shaw's Amendment No. 4 to its Schedule 13D on Gossamer Bio reports that its Valence portfolio crossed…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells since Mar 19. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q2 2026: 32 added (0 new), 17 trimmed or exited.

  • AnalystsBULLISH

    8 of 13 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$6.549 → −$3.934 over 90 days.

  • TrendDOWNTREND

    20% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
D. E. Shaw & Co., Inc.DOUBLED40,959,285$6.7M
RENAISSANCE TECHNOLOGIES LLCDOUBLED11,629,896$1.9M
BARCLAYS PLCDOUBLED7,832,522$1.3M
BlackRock, Inc.TRIM7,669,943$1.3M
Qube Research & Technologies LtdADD7,065,756$1.2M
Corient Private Wealth LPADD5,632,698$927.1K
UBS Group AGADD3,093,785$510.5K
GEODE CAPITAL MANAGEMENT, LLCTRIM2,481,605$408.7K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

13 analysts
Buy 62% rate it Buy or better
Strong Buy3Buy5Hold4Sell1Strong Sell0
12-month targets · 6 analysts

Price is below the lowest target. Median implies +938%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 26, 2026🔒 Fresh data, subscribers only
MAINTAIN
MAINTAIN
Oct 15, 2026Chardan Capital
MAINTAIN
MAINTAINBuy
Oct 13, 2026Chardan Capital
INITIATE
INITIATEBuy
Sep 21, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Aug 14, 2026Piper Sandler
MAINTAIN
MAINTAINOverweight
Jul 28, 2026Leerink Partners
UPGRADE
UPGRADEOutperform

Insider ledger

Form 4
$0
open-market buys or sells · since Mar 19
DateInsiderTypeValue
Sep 23, 2026
Cox Russell J.
Director
AWARD10,000 sh
Sep 23, 2026
Quisel John D
Director
AWARD10,000 sh
Sep 23, 2026
Drynan Skye
Director
AWARD10,000 sh
Sep 23, 2026
Nathan Steven D
Director
AWARD10,000 sh
Sep 23, 2026
Ciongoli Gregory Austin
Director
AWARD30,000 sh
Sep 23, 2026
Daniel Thomas O
Director
AWARD10,000 sh
Sep 23, 2026
Milligan Sandra
Director
AWARD10,000 sh
Aug 24, 2026
Hasnain Faheem
President & CEO
AWARD$166.0K

Earnings setup

Estimates
Nov 3
reports in 8 days
−$3.93
EPS estimate, this quarter
+40%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$3.93-$7.43–$0.80-4.3%$12.2M
Next Q-$4.93-$6.40–-$3.20-12.1%$3.0M
Current FY🔒 Fresh data, subscribers only
Next FY-$15.61-$28.80–-$2.88-7.8%$16.7M

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Trading halts
Sep 10, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 8, 2026 SEC
D. E. Shaw filed Amendment No. 5 to its Schedule 13D for Gossamer Bio, primarily to correct an understatement of…
SC 13D/A — Impact 5/10
Sep 30, 2026 Short interest report
Short Interest: GOSS up 30% to 1.2M shares
Settlement 2026-09-30 | Days to cover: 3.50 | ≈20.24% of shares outstanding (est.)
Sep 28, 2026 SEC
D. E. Shaw's Amendment No. 4 to its Schedule 13D on Gossamer Bio reports that its Valence portfolio crossed below the…
SC 13D/A — Impact 6/10
Sep 23, 2026 Insider
Cox Russell J. was granted 10,000 shares
Director
Sep 23, 2026 Insider
Quisel John D was granted 10,000 shares
Director
Sep 23, 2026 Insider
Drynan Skye was granted 10,000 shares
Director
Sep 22, 2026 SEC
In Q2 2026, a cluster of 32 institutional buyers accumulated $8.5M in Gossamer Bio (GOSS) while 17 sellers reduced…
INST-CLUSTER — Impact 4/10
Jun 30, 2026 Inst.
D. E. Shaw & — DOUBLED
40,959,285 shares ($6.7M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 3, 2026
Earnings date
GOSS Q3 2026 Earnings Before Market Open — 2026-11-03
Recent
Oct 13, 2026
Clinical Trial
Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
Phase 2 · TERMINATED
Sep 30, 2026
Short interest
Short Interest: GOSS up 30% to 1.2M shares
Settlement 2026-09-30 | Days to cover: 3.50 | ≈20.24% of shares outstanding (est.)
Sep 25, 2026
Listing
Listing Status: GOSS — Normal (was Deficient)
Gossamer Bio, Inc. - Common Stock | Nasdaq Financial Status Indicator D → N
Sep 11, 2026
Trading halt
Halt Resumed: GOSS — trading resumed after T3 (News and Resumption Times)
Halted 2026-09-10T23:50:00.000Z | Resumed 2026-09-11T13:00:00.000Z
Sep 10, 2026
Trading halt
Trading Halt: GOSS — T1 (News Pending)
Gossamer Bio, Inc. CS | Market: NASDAQ | Code: T1 — News Pending

SecBot reports

15 filings · 0 bullish · 6 bearish · 2 mixed · 7 neutral
All GOSS filing & press-release reports (15)